<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03858751</url>
  </required_header>
  <id_info>
    <org_study_id>2018p001201aim2</org_study_id>
    <nct_id>NCT03858751</nct_id>
  </id_info>
  <brief_title>Pharmacological Activation of HMN for OSA Aim 2</brief_title>
  <official_title>Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea Aim 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) is common and has major health implications but treatment
      options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
      activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
      to normal subjects. In this protocol the investigators will test the effect of LTM1201AZ,
      LTM1201AT, LTM1201AD, LTM1201AG administered before sleep on OSA phenotype traits and OSA
      severity during sleep.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea hypopnea Index (AHI, average number of events for every hour of sleep)</measure>
    <time_frame>3 nights (treatment duration)</time_frame>
    <description>Based on previous studies the investigators anticipate that active comparators will reduce AHI more effectively in subjects with moderate sleep apnea and low-to-moderate collapsibility (Vpassive &gt;50% of eupneic values). Higher AHI indicates more severe OSA, usually ranging between 10 to 110 events/hour.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201AZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTM1201AZ capsule before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201AT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTM1201AT capsule before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201AG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTM1201AG capsule before bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTM1201AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LTM1201AD capsule before bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo capsule before bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201AZ</intervention_name>
    <description>LTM1201AZ oral capsule before sleep</description>
    <arm_group_label>LTM1201AZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201AT</intervention_name>
    <description>LTM1201AT oral capsule before sleep</description>
    <arm_group_label>LTM1201AT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201AG</intervention_name>
    <description>LTM1201AG oral capsule before sleep</description>
    <arm_group_label>LTM1201AG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTM1201AD</intervention_name>
    <description>LTM1201AD oral capsule before sleep</description>
    <arm_group_label>LTM1201AD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AHI &gt; 10 events/h during NREM supine sleep

        Exclusion Criteria:

          -  Any medical condition other than well controlled hypertension and mild diabetes.

          -  Any medication known to influence breathing, sleep/arousal, or muscle physiology.

          -  Claustrophobia.

          -  Inability to sleep supine.

          -  Allergy to any of the medications tested in the protocol.

          -  History of kidney stones, hypercalcemia, primary hyperparathyroidism, sarcoidosis,
             hypervitaminosis D.

          -  Individuals with underlying cardiac disease, such as arrhythmias.

          -  Individuals taking psychiatric medications, such as an MAO-I, SSRI or SNRI, or any of
             the studied medications for medical care.

          -  For women: Pregnancy.

          -  Pulmonary hypertension

          -  Severe OSA with a mean SaO2 lower than 88%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Calianese, Research Assistant</last_name>
      <phone>617-732-8977</phone>
      <email>ncalianese@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Hess, RPSGT</last_name>
      <phone>617-732-8976</phone>
      <email>lhess1@bwh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Luigi Taranto Montemurro</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

